恒瑞医药(600276.SH)：HRS-3095片获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-3095 tablets, a self-developed small molecule compound targeting immune cells, which shows promising therapeutic effects for allergic diseases [1] Group 1 - The company’s subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., is set to initiate clinical trials for HRS-3095 tablets [1] - HRS-3095 tablets are designed to treat allergic diseases effectively [1]